ISAL 2019 | Improving adult ALL treatment: pediatric regimens & adding inotuzumab
Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the CALCG 10403 study (NCT00558519), which investigated the use of a pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia (ALL). Doses and schedule in this trial were identical to the Children’s Oncology Group study AALL0232. Prof. Stone then highlights a study going a step further by adding inotuzumab ozogamicin (NCT01363297). This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
Get great new content delivered to your inboxSign up